Masitinib in Oncology

Prostate cancer is one of the most common types of cancer in men. Masitinib is currently investigated in first-line metastatic castrate-resistant prostate cancer (mCRPC). This patient population consists of patients who have disease progression despite androgen depletion therapy (castration) treatment. There is still a need for more effective first-line treatment of mCRPC since recent therapies…

Masitinib in Inflammatory Diseases

The severity of asthma can be graded from mild intermittent disease, with little impact on everyday life, through to severe disease with permanent symptoms and serious limitation of normal activities. Data suggests that mast cells are involved in allergic and anaphylactic reactions, playing an important role in hypersensitivity and inflammatory processes of the disease and…

AB8939

AB8939 is a new small-molecule drug that binds to tubulin and induces a rapid destabilisation of microtubules. Through disorganisation of microtubules, AB8939 is able to induce the apoptosis at nanomolar concentration of a wide panel of tumor cell lines, in particular hematopoietic tumor cell lines (i.e. cancers that affect the blood and lymph system) and…

Calendrier Financier

Choisir une année : 2017 2016 2015 2014 2013 Calendrier financier 2017 01/01/2017 – Calendrier financier pour l’année 2017 Calendrier financier 2016 23/02/2016 – Calendrier financier pour l’année 2016 Calendrier financier 2015 29/01/2015 – Calendrier financier pour l’année 2015 Calendrier financier 2014 29/11/2013 – Calendrier financier pour l’année 2014 Calendrier financier 2015 21/12/2012 – Calendrier…

Autres informations

Statuts de la société 12/06/2017 – Mis à jour au 24 avril 2017 Mise à disposition d’un prospectus à l’occasion de l’admission sur Euronext Paris d’un nombre maximum de 2 819 909 actions ordinaires nouvelles 10/03/2017 – Actions susceptibles d’être émises sur exercices de bons de souscription d’actions dans le cadre du programme d’Equity Line…